Selected Recent Publications:

1)  Lenis AT, Lec PM, Chamie K.  Urinary Diversion.  JAMA. 2020 Dec 1;324(21):2222. doi: 10.1001/jama.2020.17604. PMID: 33258891

2)  Christian-Miller N, Lenis AT, Fero KE, Madrigral J, Eleswarapu SV, Chamie K, Benharash  P.   Risk factors for penile fracture compared with a surgical control cohort in the United States: the role of substance abuse.   Asian J Androl. 2020 Nov 27. doi: 10.4103/aja.aja_70_20. Online ahead of print. PMID: 33243961

3)  Lenis AT, Lec PM, Chamie K, Mshs MD.  Bladder Cancer: A Review. JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598. PMID: 33201207

4)  Lenis AT, Lec PM, Chamie K.  Bladder Cancer.  JAMA. 2020 Nov 17;324(19):2006. doi: 10.1001/jama.2020.17601. PMID: 33201205

5)  Lec PM, Venkataramana A, Lenis AT, Fero KE, Sharma V, Golla V, Gollapudi K, Blumberg J,   Chamie K.  Trends in management of ureteral urothelial carcinoma and effects on survival: a hospital-based registry study.  Urol Oncol. 2020 Oct 1:S1078-1439(20)30402-6. doi: 10.1016/j.urolonc.2020.08.033. Online ahead of print. PMID: 33012575

6)  Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.  A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.  J Immunother. 2020 Nov/Dec;43(9):273-282. doi: 10.1097/CJI.0000000000000336. PMID: 32925563

7)  Michel J, Lenis AT, Lec PM, Golla V, Johnson DC, Gollapudi K, Blumberg J, Shuch BM, Chamie K.  Analysis of guideline recommended use of renal mass biopsy and association with treatment.  Can J Urol. 2020 Aug;27(4):10285-10293. PMID: 32861253

8) Chamie K, Golla V, Lenis AT, Lec PM, Rahman S, Viscusi ER.  Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review.  J Gastrointest Surg. 2020 Aug 10. doi: 10.1007/s11605-020-04671-x. Online ahead of print. PMID: 32779081

9)  Drakaki A, Pantuck A, Mhatre SK, Dhillon PK, Davarpanah N, Degaonkar V, Surinach A, Chamie K, Grivas P. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.  Urol Oncol. 2021 Jan;39(1):76.e15-76.e22. doi: 10.1016/j.urolonc.2020.07.011. Epub 2020 Aug 8. PMID: 32778476

10)  Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.  Lancet Oncol. 2020 Jun;21(6):776-785. doi: 10.1016/S1470-2045(20)30147-9. Epub 2020 Apr 29. PMID: 32631491

11)  Lec PM, Lenis AT, Golla V, Brisbane W, Shuch B, Garraway IP, Reiter RE, Chamie K.  The Role of Opioids and Their Receptors in Urological Malignancy: A Review.  J Urol. 2020 Dec;204(6):1150-1159. doi: 10.1097/JU.0000000000001156. Epub 2020 Jun 9. PMID: 32516030

12)  Lenis AT, Lec PM, Michel J, Brisbane W, Golla V, Sharma V, Gollapudi K, Blumberg J, Chamie K.  Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival.  Urol Oncol. 2020 Oct;38(10):796.e7-796.e14. doi: 10.1016/j.urolonc.2020.04.027. Epub 2020 May 20. PMID: 32446641

13)  Lec PM, Lenis AT, Brisbane W, Sharma V, Golla V, Gollapudi K, Blumberg J, Drakaki A, Bergman J, Chamie K.  Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study.  Urol Oncol. 2020 Nov;38(11):854.e1-854.e9. doi: 10.1016/j.urolonc.2020.04.029. Epub 2020 May 17. PMID: 32430252

14)   Kunitsky K, Lec PM, Brisbane W, Lenis AT, Chamie K.  Sodium Fluorescein for Identification of Intraoperative Urine Leaks During Partial Nephrectomy.  Urology. 2020 Aug;142:249. doi: 10.1016/j.urology.2020.04.084. Epub 2020 May 6. PMID: 32387291

15)  Lenis AT, Golla V, Lec PM, Johnson DC, Faiena I, Lee C, Rahman S, Chamie K.  The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy.  World J Urol. 2020 Dec;38(12):3113-3119. doi: 10.1007/s00345-020-03117-y. Epub 2020 Feb 18. PMID: 32072229

16)  Golla V, Lenis AT, Faiena I, Chamie K.   Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage.  Rev Urol. 2019;21(4):145-153. PMID: 32071562

17)  Pooli A, Salmasi A, Johnson DC, Lenis AT, Faiena I, Lebacle C, Golla V, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.  Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors.  Urol Oncol. 2020 Jan;38(1):1.e17-1.e23. doi: 10.1016/j.urolonc.2019.08.016. Epub 2019 Sep 16. PMID: 31537483

18)  Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.  Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.     Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17. PMID: 31411998

19)  Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU.  Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.  Eur Urol Oncol. 2019 Feb 1:S2588-9311(19)30007-0. doi: 10.1016/j.euo.2019.01.006. Online ahead of print. PMID: 31411981

20) Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group.   Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.  N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. PMID: 31340094

21)  Michel J, Goel AN, Golla V, Lenis AT, Johnson DC, Chamie K, Litwin MS.  Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty. Urology. 2019 Nov;133:25-33. doi: 10.1016/j.urology.2019.04.057. Epub 2019 Jul 12. PMID: 31306670

22)  Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.  Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.  Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14. PMID: 31017086

23)  Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.  Urol Oncol. 2019 Sep;37(9):577.e9-577.e16. doi: 10.1016/j.urolonc.2019.03.009. Epub 2019 Mar 28. PMID: 30930099

24)  Donin NM, Kwan L, Lenis AT, Drakaki A, Chamie K.  Second primary lung cancer in United States Cancer Survivors, 1992-2008.  Cancer Causes Control. 2019 May;30(5):465-475. doi: 10.1007/s10552-019-01161-7. Epub 2019 Mar 21. PMID: 30900065

25)  Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.  Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.  Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21. PMID: 30790015

26)  Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.  World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. PMID: 30684034

27)  Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, Giffin LC, Gonzalez LE, Chamie K. Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer.  Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1036-1044. doi: 10.1158/1055-9965.EPI-18-0893. Epub 2018 Dec 28. PMID: 30593457

28)  Faiena I, Rosser CJ, Chamie K, Furuya H.  Diagnostic biomarkers in non-muscle invasive bladder cancer.  World J Urol. 2019 Oct;37(10):2009-2016. doi: 10.1007/s00345-018-2567-1. Epub 2018 Nov 22. PMID: 30467596

29)  Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.  Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better? Urol Oncol. 2019 Jan;37(1):63-70. doi: 10.1016/j.urolonc.2018.10.018. Epub 2018 Nov 13. PMID: 30446452

30)  Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K.  Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.  BMC Urol. 2018 Oct 24;18(1):93. doi: 10.1186/s12894-018-0408-6. PMID: 30355350

31)  Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.   Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.  Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6. PMID: 30345422

32)  Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.   Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.  World J Urol. 2019 Jun;37(6):1157-1164. doi: 10.1007/s00345-018-2506-1. Epub 2018 Sep 28. PMID: 30267197

33)  Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.   Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.  Urol Oncol. 2018 Dec;36(12):527.e13-527.e19. doi: 10.1016/j.urolonc.2018.08.009. Epub 2018 Sep 15. PMID: 30228094

34)  Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE.  Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center.  Urol Oncol. 2018 Sep;36(9):401.e19-401.e25. doi: 10.1016/j.urolonc.2018.06.006. Epub 2018 Jul 29. PMID: 30064933

35)  Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.  Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.  World J Urol. 2018 Nov;36(11):1825-1833. doi: 10.1007/s00345-018-2327-2. Epub 2018 May 11. PMID: 29752514

36)  Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K.  Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.  Urol Pract. 2018 Mar;5(2):132-138. doi: 10.1016/j.urpr.2017.02.012. Epub 2017 Mar 2. PMID: 29577063

37)  Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.  Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.  Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. PMID: 29416316

38)  Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K.  Trends in urinary diversion after radical cystectomy for urothelial carcinoma.  World J Urol. 2018 Mar;36(3):409-416. doi: 10.1007/s00345-017-2169-3. Epub 2018 Jan 3. PMID: 29299664

39)  Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A.  The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.  Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. PMID: 29199023

40)  Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.   Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.   Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8. PMID: 29128421

41)  Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.  Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.  Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2. PMID: 29103965

42)  Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K.  Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.  Urol Oncol. 2018 Jan;36(1):9.e1-9.e9. doi: 10.1016/j.urolonc.2017.09.001. Epub 2017 Oct 20. PMID: 29066013

43)  Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB.  Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.  Clin Genitourin Cancer. 2017 Jul 26:S1558-7673(17)30215-X. doi: 10.1016/j.clgc.2017.07.018. Online ahead of print. PMID: 28826932

44)  Tan HJ, Litwin MS, Chamie K, Saliba D, Hu JC.   Trends in Aging-Related Services During Nephrectomy: Implications for Surgery in an Aging Population.   J Am Geriatr Soc. 2017 Oct;65(10):2290-2296. doi: 10.1111/jgs.15046. Epub 2017 Aug 11. PMID: 28801975

45)  Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.  Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26. PMID: 28755959

46)  Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K.   Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.  J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4. PMID: 28479237

47)  Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO Jr, Williams MA, Giordano SH, Kim SP, Kamat AM.  Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.  Cancer Causes Control. 2017 Jul;28(7):755-766. doi: 10.1007/s10552-017-0902-2. Epub 2017 May 5. PMID: 28477210

48)  Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.   A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.  Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26. PMID: 28341495

49)  Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF.  Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.  Cancer. 2017 May 1;123(9):1617-1624. doi: 10.1002/cncr.30506. Epub 2017 Jan 18. PMID: 28099688

50)  Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.  Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.  Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3. PMID: 28065395

51)  Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IPImpact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.  Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20. PMID: 27997745

52)  Tan HJ, Shirk JD, Chamie K, Litwin MS, Hu JC. Patient Function and the Value of Surgical Care for Kidney Cancer.   J Urol. 2017 May;197(5):1200-1207. doi: 10.1016/j.juro.2016.12.012. Epub 2016 Dec 13. PMID: 27986531

53)  Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.    Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30. PMID: 27903751

54)  Lenis AT, Chamie K.  Regionalization of Cystectomy: Importance of Care Coordination, Bundled Payments and Surgical Ownership.  J Urol. 2017 Feb;197(2):278-279. doi: 10.1016/j.juro.2016.11.073. Epub 2016 Nov 11. PMID: 27845149

55)  Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.   Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial .  JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419. PMID: 27787547

56)  Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K.  Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.  Urology. 2017 Jan;99:270-277. doi: 10.1016/j.urology.2016.09.039. Epub 2016 Oct 5. PMID: 27720772

57)  Krishna S, Fan Y, Jarosek S, Adejoro O, Chamie K, Konety B.  Racial Disparities in Active Surveillance for Prostate Cancer.  J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3. PMID: 27596691

58)  Williams SB, Duan Z, Chamie K, Hoffman KE, Smith BD, Hu JC, Shah JB, Davis JW, Giordano SH.  Risk of hospitalisation after primary treatment for prostate cancer.  BJU Int. 2017 Jul;120(1):48-55. doi: 10.1111/bju.13647. Epub 2016 Sep 16. PMID: 27561186

59)  Tan HJ, Chamie K, Daskivich TJ, Litwin MS, Hu JC.   Patient function, long-term survival, and use of surgery in patients with kidney cancer.  Cancer. 2016 Dec 15;122(24):3776-3784. doi: 10.1002/cncr.30275. Epub 2016 Aug 12. PMID: 27518165

60)  Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K.  Immunotherapy for the Treatment of Urothelial Carcinoma.  J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25. PMID: 27460757

61)  Lenis AT, Donin NM, Litwin MS, Saigal CS, Lai J, Hanley JM, Konety BR, Chamie K; Urologic Diseases in America Project.  Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.  Clin Genitourin Cancer. 2017 Feb;15(1):e25-e31. doi: 10.1016/j.clgc.2016.06.014. Epub 2016 Jun 25. PMID: 27432529

62)  Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K.  Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.  Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32. doi: 10.1158/1055-9965.EPI-16-0226. Epub 2016 Jul 14. PMID: 27418270

63)  Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K.  Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.  Cancer. 2016 Oct;122(19):3075-86. doi: 10.1002/cncr.30164. Epub 2016 Jul 5. PMID: 27377470

64)  Filson CP, Tan HJ, Chamie K, Laviana AA, Hu JC.  Determinants of radical cystectomy operative time.  Urol Oncol. 2016 Oct;34(10):431.e17-24. doi: 10.1016/j.urolonc.2016.05.006. Epub 2016 Jun 29. PMID: 27372282

65) Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.  Eur Urol Focus. 2017 Apr;3(2-3):258-264. doi: 10.1016/j.euf.2016.04.008. Epub 2016 May 13. PMID: 28753760

66)  Chamie K, Williams SB, Hershman DL, Wright JD, Nguyen PL, Hu JC.  Population-based assessment of determining predictors for quality of prostate cancer surveillance.  Cancer. 2015 Dec 1;121(23):4150-7. doi: 10.1002/cncr.29574. Epub 2015 Aug 26. PMID: 26307939  

67)  Chamie K, Williams SB, Hu JC.   Population-Based Assessment of Determining Treatments for Prostate Cancer.  JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192. PMID: 26182305

68)  Williams SB, Chamie K, Hu JC.  Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer-Reply.  JAMA Oncol. 2015 Aug;1(5):689-90. doi: 10.1001/jamaoncol.2015.1199. PMID: 26181144

69)  Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.  Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.  Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29. PMID: 25823535

70)  Lenis AT, Chamie K.  Bladder cancer in 2014: From the genomic frontier to immunotherapeutics.   Nat Rev Urol. 2015 Feb;12(2):74-6. doi: 10.1038/nrurol.2014.369. Epub 2015 Jan 6. PMID: 25558841

71)  Chamie K, Ballon-Landa E, Daskivich TJ, Bassett JC, Lai J, Hanley JM, Konety BR, Litwin MS, Saigal CS; Urologic Diseases in America Project. Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer.  Urol Oncol. 2015 Jan;33(1):20.e9-20.e17. doi: 10.1016/j.urolonc.2014.08.016. Epub 2014 Nov 7. PMID: 25443267

72)  Chamie K, Ballon-Landa E, Bassett JC, Daskivich TJ, Leventhal M, Deapen D, Litwin MS.  Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.  Cancer. 2015 Feb 1;121(3):379-85. doi: 10.1002/cncr.29071. Epub 2014 Oct 22. PMID: 25339141

73)  Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, Trinh QD, Sun M, Nguyen PL, Lipsitz SR.  Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.  Urol Oncol. 2015 Feb;33(2):69.e29-34. doi: 10.1016/j.urolonc.2014.06.003. Epub 2014 Jul 10. PMID: 25017694